CEACAM5 and neoplasm: Patients with decreased CEA after treatment had better outcomes and longer survival; CEA declination at week 6 and 12 post-treatment was associated with52.3% and 59.4% lower risk of tumor progression, respectively, and they were associated with 45.7% and 38.0% lower risk of death.